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Abstract Human serum paraoxonase (PON1) associated with
high density lipoprotein (HDL) has been postulated to have a role
in protecting low density lipoprotein (LDL) against oxidative
modification, which has led to the proposal that PON1 is an anti-
atherogenic, anti-inflammatory enzyme. PON1 has two geneti-
cally determined polymorphic sites giving rise to amino-acid
substitutions at positions 55 (LCM) and 192 (RCQ) and
therefore 4 potential alloenzymes. We have examined the effects
of these molecular polymorphisms on the ability of HDL to
protect LDL from oxidative modification. HDL protected LDL
from oxidative modification, whatever the combination of PON1
alloenzymes present in it. However, HDL from QQ/MM
homozygotes was most effective at protecting LDL while HDL
from RR/LL homozygotes was least effective. Thus after 6 h of
co-incubation of HDL and LDL with Cu2+ PON1-QQ HDL
retained 57 þ 6.3% of its original ability to protect LDL from
oxidative modification, while PON1-QR HDL retained less at
25.1 þ 4.5% (P60.01) and PON1-RR HDL retained only
0.75 þ 0.40% (P60.005). In similar experiments HDL from
LL and LM genotypes retained 21.8 þ 7.5% and 29.5 þ 6.6%
(P = NS), respectively, of their protective ability, whereas
PON1-MM HDL maintained 49.5 þ 5.3% (P60.01). PON1
polymorphisms may affect the ability of HDL to impede the
development of atherosclerosis and to prevent inflammation.
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1. Introduction
The oxidative modi¢cation of low density lipoprotein
(LDL) in the artery wall is currently believed to be central
to the pathogenesis of atherosclerosis [1]. Therefore, mecha-
nisms that prevent the oxidation of LDL could be anti-athe-
rogenic. One such mechanism which has received increasing
attention in recent years is the prevention of LDL oxidation
by high density lipoprotein (HDL) [2]. We were the ¢rst to
show that HDL decreased the accumulation of lipid peroxides
on LDL by a mechanism that was at least partly enzymatic in
nature [3]. We have subsequently shown that the enzyme
paraoxonase (PON1), located on HDL, is largely responsible
for HDL’s ability to metabolise lipid peroxides on LDL [4,5].
These ¢ndings have subsequently been con¢rmed and ex-
tended by others [6,7].
Serum PON1 activity is decreased in coronary heart disease
(CHD) [7,8] and in both insulin dependent and non-insulin
dependent diabetes (IDDM and NIDDM), particularly when
peripheral neuropathy is present [9]. These ¢ndings have led
to the theory that PON1 may impede lipid peroxidation of
LDL and perhaps nerve membranes, which are themselves
related to atherogenesis and neuropathy.
PON1 activity towards paraoxon is genetically determined
by two polymorphisms within the alleles acting at a single
autosomal locus. The ¢rst of these pairs reported involved
an amino acid substitution at position 192, giving rise to
two alloenzymes with low activity (glutamine at position
192) and high activity (arginine at position 192) towards para-
oxon [10,11]. This polymorphism has been found to be sub-
strate speci¢c; the alloenzyme activity is the opposite way
round to that of paraoxon with certain substrates such as
diazoxon [12]. There also exists a second polymorphism of
the human PON1 gene a¡ecting amino acid 55, giving rise
to a leucine (L-allele) substitution for methionine (M-allele).
This has also been found to modulate activity towards para-
oxon [13,14].
Four recent case control studies have indicated the PON1^
192 polymorphism is related to CHD [15^18] while three
others have not shown this relationship [18^20]. In the pos-
itive case control studies it was the R-allele (with high activity
towards paraoxon) which was associated with CHD. This led
to the hypothesis that the R-alloenzyme was less able to pre-
vent the accumulation of lipid peroxides on LDL, i.e. this
activity of PON1 might resemble the di¡erential activity to-
wards diazoxon rather than paraoxon. One study has sug-
gested that the PON1^55 L-allele is a risk factor for CHD
in NIDDM [13]. However, nothing is known regarding the
e¡ect of the 55 polymorphism on the ability of PON1 to
hydrolyse lipid peroxides.
In order to answer these questions we have determined the
e¡ect of the two PON1 polymorphisms on the ability of HDL
to prevent the accumulation of lipid peroxides on LDL.
2. Methods
2.1. Subjects
Thirty-six healthy, unrelated volunteers (18 men) aged 22^60 years
participated in the study which was approved by Central Manchester
Area Health Authority Clinical Ethical Committee. Volunteers were
either sta¡ of the Manchester Royal In¢rmary or attending for a
routine health check at a local GP surgery or were sta¡ of two local
factories. All subjects were free of ischaemic heart disease, as de¢ned
by a lack of history of angina and no previous myocardial infarction.
Subjects with peripheral vascular disease, diabetes mellitus, renal dis-
ease, hepatic disease and hyperlipidaemia or hypertension or receiving
any medication were also excluded.
2.2. Blood sampling and DNA extraction
Venous blood was obtained from the subjects between 9 and 10
a.m. after a 12-h fast. Serum and EDTA plasma were obtained by
low-speed centrifugation. Serum was stored at 320‡C before further
analysis. DNA was extracted from white blood cells left at the inter-
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face of the plasma after centrifugation using a Split-second kit (Boehr-
inger-Mannheim).
2.3. Analysis of paraoxonase activity
PON1 activity was measured by adding serum to 1 ml Tris-HCl
bu¡er (100 mmol/l, pH 8.0) containing 2 mmol/l CaCl2 and 5.5 mmol/
l paraoxon (0,0-diethyl-0-p-nitrophenylphosphate; Sigma Chemical
Co.). The rate of generation of p-nitrophenol was determined at 405
nm, 25‡C, with the use of a continuously recording spectrophotometer
(Beckman Du-68).
2.4. Paraoxonase genotype determination
PON1 genotypes were determined following PCR according to pre-
viously published protocols [10,11].
Genotype was assigned by two people independently with no
knowledge of the source of the samples.
2.5. E¡ect of paraoxonase genotype on ability of HDL to prevent LDL
lipid peroxidation
LDL (d 1.019^1.063 g/ml) was prepared by sequential ultracentrif-
ugation [21]. HDL (d 1.063^1.21 g/ml) was prepared by sequential
ultracentrifugation in the presence of 5 mM CaCl2. Under these con-
ditions 70^80% of PON1 remains associated with HDL and no di¡er-
ences in the loss of di¡erent alloenzymes from HDL are found [22].
LDL (1.5 mg) or autologous HDL (1.5 mg) or LDL+HDL (1.5 mg
each) were incubated in a total volume of 1 ml of EDTA-free PBS at
37‡C. Oxidation was initiated by the addition of 5 WM CuSO4 and the
generation of lipid peroxides in LDL determined using cholesterol-
iodide reagent, at various time intervals up to 6 h, as described pre-
viously [3^5].
2.6. Statistical analysis
Statistical analysis was conducted using the SPSS statistical package
for Windows 95. Di¡erences in parameters between genotype was
sought by Student’s t-test for variables with a gaussian distribution
and by the Mann-Whitney U-test for variables with a non-gaussian
distribution.
3. Results
In the 36 study subjects the distribution of the PON1 geno-
types was 39% QQ, 47% QR and 14% RR for the PON-192
genotype (gene frequency = 0.62 A; 0.38 B) and 33% LL, 47%
LM and 20% MM for the PON-55 genotype (gene fre-
quency = 0.57 L; 0.43 M. The e¡ect of the two PON1 poly-
morphisms on the serum hydrolysis of paraoxon in the 36
subjects in this study was similar to our previous ¢ndings in
a much larger healthy population of 279 individuals [14] (re-
sult not shown), indicating the study population to be repre-
sentative of the general population.
The ability of HDL to protect LDL against oxidative mod-
i¢cation was similar regardless of the PON1 alloenzymes it
contained for at least the ¢rst 2 h of incubation (Figs. 1
and 2). In the case of the PON1^192 polymorphism, HDL
from RR homozygotes appeared less e¡ective in decreasing
LDL lipid peroxide accumulation at around 4 h (Fig. 1). After
6 h, signi¢cant di¡erences between HDL from the di¡erent
PON1^192 genotypes were apparent. They were expressed as
the proportionate decrease in LDL lipid peroxides when HDL
was present as opposed to when it was absent. HDL from
PON1 homozygotes for the QQ alloenzyme retained
57.0 þ 10.4% (mean þ S.D.) of its ability to prevent LDL lipid
peroxide generation. However, HDL heterozygous for the Q
and R alloenzymes retained less protective ability at
25.0 þ 9.5% (P6 0.01 compared to QQ-HDL) and HDL
from homozygotes for the PON-RR alloenzyme retained
only 0.75 þ 0.1% of its original ability to protect LDL against
oxidative modi¢cation (P6 0.005 compared to AA-HDL)
(Fig. 3a).
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Fig. 1. E¡ect of the PON-192 polymorphism on the ability of HDL
to protect LDL against oxidative modi¢cation. LDL and HDL were
isolated by ultracentrifugation. 1.5 mg of LDL and 1.5 mg of HDL
protein were co-incubated in 1 ml of PBS at 37‡C. Oxidation was
initiated by the addition of 5 WM CuSO4. Sub-samples were with-
drawn after 0.5, 1, 2, 4 and 6 h of incubation and LDL lipid perox-
ides determined as described [3]. Data are mean þ S.D. * Signi¢-
cantly di¡erent from QQ-HDL, P6 0.01. ** Signi¢cantly di¡erent
from QQ-HDL, P6 0.005. b9b, LDL alone; a- - -a, LDL+QQ
HDL; E- - -E, LDL+QR HDL; O- - -O, LDL+RR HDL.
Fig. 2. E¡ect of the PON-55 polymorphism on the ability of HDL
to protect LDL against oxidative modi¢cation. LDL and HDL were
isolated and incubated as described in the legend to Fig. 1. Data
are mean þ S.D. * Signi¢cantly di¡erent from LL and LM HDL,
P6 0.01. b9b, LDL alone; a- - -a, LDL+LL HDL; E- - -E,
LDL+LM HDL; O- - -O, LDL+MM HDL.
Fig. 3. E¡ect of the PON-55 (a) and 192 (b) polymorphisms on the
ability of HDL to protect LDL against oxidative modi¢cation. LDL
and HDL were isolated and incubated as described in the legend to
Fig. 1. Bars represent the mean value with standard error bars.
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The PON-55 polymorphism also a¡ected the ability of
HDL to protect LDL against oxidative modi¢cation (Fig.
2). There were no signi¢cant di¡erences between the geno-
types at 1, 2 and 4 h. However, at 6 h a signi¢cant di¡erence
between HDL from the MM homozygotes and LM and LL
genotypes was evident (Fig. 3b). Thus after 6 h of incubation
HDL containing LL and LM alloenzymes retained
21.8 þ 7.5% and 29.5 þ 6.6% of their ability to protect LDL
against oxidation, respectively (P = NS). Whilst HDL contain-
ing MM alloenzymes maintained 49.5 þ 11.4% of its ability to
protect LDL against oxidation (P6 0.01 compared to both
LM and LL HDL).
4. Discussion
PON1 is important in the detoxi¢cation of both OP insec-
ticides and nerve gases [10^12] and pro-atherogenic phospho-
lipid hydroperoxides generated during the oxidative modi¢ca-
tion of LDL [4^7]. The results presented here indicate a
critical role for the amino acid substitutions at both positions
355 and 3192 in determining the activity of PON1 towards
lipid peroxides. We have previously shown that individuals
homozygous for the AA/MM genotypes have greatly reduced
ability to detoxify paraoxon [14]. The present series of normal
volunteers were typical in this respect.
The inverse relationship between plasma HDL concentra-
tion and CHD has been known from epidemiological studies
for many years [23]. The mechanism by which HDL might
confer protection from CHD has been the subject of much
debate, but has generally been considered to be due to the
central role of HDL in reverse-cholesterol transport. More
recently a second mechanism has been proposed; the protec-
tion of LDL against oxidative modi¢cation by HDL [2]. Our
initial observation that PON1 isolated from HDL was ex-
tremely potent in protecting LDL against oxidation [4,5],
has subsequently been con¢rmed and extended by others
[6,7]. More recently it has been reported that immunostaining
for PON1 in the human artery wall increases as atheroma
progresses, possibly in response to the increasingly pro-oxi-
dant environment [24]. PON1 is present in human tissue £uid
[25] and could potentially therefore protect LDL even after it
has crossed the vascular endothelium and perhaps cell mem-
branes from oxidation.
In the present investigation we have shown that the poly-
morphisms of PON1 due to amino acid substitutions at posi-
tions 55 and 192 can greatly modify the e⁄cacy of HDL in
protecting LDL against lipid peroxidation. With regard to the
192 polymorphism PON1 QQ-HDL was most e⁄cient at pro-
tecting LDL against oxidative modi¢cation and PON1 RR-
HDL least e⁄cient. This may explain why in some case con-
trol studies the PON1 R-allele is associated with CHD [15^
18]. LDL is believed to be sequestered in the artery wall where
it becomes oxidised and pro-atherogenic [1]. A protective
mechanism retaining its e¡ectiveness over several hours might
therefore be crucially important in determining the rate of
atherogenesis. HDL containing the PON1-Q alloenzyme in
the present study retained 6 times more protective e¡ect
over 6 h than the R-alloenzyme. The 355 polymorphism
also a¡ected the e⁄ciency with which HDL protected LDL
against lipid peroxidation. PON1 MM-HDL retained twice as
much ability to protect LDL after 6 h as did HDL from either
LM heterozygotes or LL homozygotes. HDL from those in-
dividuals who are homozygous for both the Q and M poly-
morphisms is the most e⁄cient at protecting LDL, and these
individuals should according to our hypothesis be least sus-
ceptible to developing CHD. HDL from individuals homozy-
gous for the R and L polymorphisms was least protective and
these individuals should be more susceptible to CHD develop-
ment, as suggested by the only case control study of this poly-
morphism thus far reported [13].
The reasons why the polymorphisms have such a dramatic
e¡ect on substrate speci¢city are unknown. However, with
regard to lipid peroxides, the e¡ect on the polymorphism re-
sembles the hydrolysis of diazoxon rather than of paraoxon.
Whilst the results presented here suggest that the PON1 al-
loenzyme located on HDL is a major determinant of its ability
to protect LDL against oxidation, other HDL-associated en-
zymes, such as platelet-activating factor acetylhydrolase and
lecithin/cholesterol acyltransferase, have been shown to me-
tabolise LDL phospholipid hydroperoxides [26,27], and it re-
mains possible that PON1 exerts its e¡ect in protecting LDL
against oxidative modi¢cation in conjunction with other en-
zymes present in HDL.
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